Zealand reports positive Phase 2 petrelintide data in diabetes and obesity
Zealand Pharma reported positive topline Phase 2 ZUPREME-2 results for petrelintide in people with overweight or obesity and type 2 diabetes. After 28 weeks, average weight loss reached 9.2% in the highest-performing treatment arm, compared with 2.0% for placebo, while the study met its primary endpoint. Zealand said it and Roche have begun a three-study Phase 3a program for the drug.
Why it matters
The results provide clinical support for Zealand's and Roche's ongoing late-stage development of petrelintide in chronic weight management. Zealand said the data also support petrelintide's potential as a standalone option for patients who have both excess weight and type 2 diabetes.
Key facts
- 1ZUPREME-2 enrolled 220 U.S. participants with overweight or obesity and type 2 diabetes. marketscreener.com
- 2At week 28, mean weight loss across petrelintide arms ranged from 7.4-9.2%, versus 2.0% in the placebo arm. marketscreener.com
- 3Participants receiving petrelintide had a placebo-adjusted HbA1c reduction of 0.61%-0.88%. marketscreener.com
- 4Discontinuations caused by gastrointestinal adverse events were 1.9% with petrelintide and 1.7% with placebo. marketscreener.com
- 5Zealand and Roche's Phase 3a program comprises ZUPREME-3, ZUPREME-4, and ZUPREME-5 and is expected to enroll approximately 7,000 participants in total. marketscreener.com
- 6Zealand shares fell about 3% on Thursday following the results announcement. investing.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.